U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C21H23Cl2NO6
Molecular Weight 456.3171
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CLEVIDIPINE

SMILES

CCCC(=O)OCOC(=O)C1=C(C)NC(=C(C1c2cccc(c2Cl)Cl)C(=O)OC)C

InChI

InChIKey=KPBZROQVTHLCDU-UHFFFAOYSA-N
InChI=1S/C21H23Cl2NO6/c1-5-7-15(25)29-10-30-21(27)17-12(3)24-11(2)16(20(26)28-4)18(17)13-8-6-9-14(22)19(13)23/h6,8-9,18,24H,5,7,10H2,1-4H3

HIDE SMILES / InChI

Molecular Formula C21H23Cl2NO6
Molecular Weight 456.3171
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Clevidipine is a dihydropyridine calcium channel blocker. Clevidipine is marketed under the trade name Cleviprex, indicated for the reduction of blood pressure (BP) when oral therapy is not feasible or not desirable. Clevidipine is a dihydropyridine L-type calcium channel blocker. L-type calcium channels mediate the influx of calcium during depolarization in arterial smooth muscle. Experiments in anesthetized rats and dogs show that clevidipine reduces mean arterial blood pressure by decreasing systemic vascular resistance. Clevidipine does not reduce cardiac filling pressure (pre-load), confirming lack of effects on the venous capacitance vessels.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
CLEVIPREX

Approved Use

Cleviprex is indicated for the reduction of blood pressure when oral therapy is not feasible or not desirable. Cleviprex is a dihydropyridine calcium channel blocker indicated for the reduction of blood pressure when oral therapy is not feasible or not desirable. (1)

Launch Date

1.21754878E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3.36 ng/mL
2 mg/h other, intravenous
dose: 2 mg/h
route of administration: Intravenous
experiment type: OTHER
co-administered:
CLEVIDIPINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
122 ng × h/mL
2 mg/h other, intravenous
dose: 2 mg/h
route of administration: Intravenous
experiment type: OTHER
co-administered:
CLEVIDIPINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
4.18 min
2 mg/h other, intravenous
dose: 2 mg/h
route of administration: Intravenous
experiment type: OTHER
co-administered:
CLEVIDIPINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
15 min
2 mg/h other, intravenous
dose: 2 mg/h
route of administration: Intravenous
experiment type: OTHER
co-administered:
CLEVIDIPINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
0.5%
2 mg/h other, intravenous
dose: 2 mg/h
route of administration: Intravenous
experiment type: OTHER
co-administered:
CLEVIDIPINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
9.58 ug/kg/min 1 times / day single, intravenous
Recommended
Dose: 9.58 ug/kg/min, 1 times / day
Route: intravenous
Route: single
Dose: 9.58 ug/kg/min, 1 times / day
Sources: Page: -
unhealthy
n = 1301
Health Status: unhealthy
Condition: hypertension
Sex: M+F
Population Size: 1301
Sources: Page: -
Disc. AE: Hypotension, Hypertension...
AEs leading to
discontinuation/dose reduction:
Hypotension
Hypertension
Haemorrhage
Flushing
Pallor
Atrial fibrillation
Ventricular fibrillation
Bradycardia
Myocardial infarction
Tachycardia
Supraventricular tachycardia
Atrial flutter
Atrioventricular block complete
Atrioventricular block second degree
Cardiac failure congestive
Cardio-respiratory arrest
Low cardiac output syndrome
Myocardial ischaemia
Supraventricular extrasystoles
Ventricular tachycardia
Hypoxia
Acute respiratory failure
Pulmonary hypertension
Respiratory arrest
Incision site complication
Thrombocytopenia
Sources: Page: -
AEs

AEs

AESignificanceDosePopulation
Acute respiratory failure Disc. AE
9.58 ug/kg/min 1 times / day single, intravenous
Recommended
Dose: 9.58 ug/kg/min, 1 times / day
Route: intravenous
Route: single
Dose: 9.58 ug/kg/min, 1 times / day
Sources: Page: -
unhealthy
n = 1301
Health Status: unhealthy
Condition: hypertension
Sex: M+F
Population Size: 1301
Sources: Page: -
Atrial fibrillation Disc. AE
9.58 ug/kg/min 1 times / day single, intravenous
Recommended
Dose: 9.58 ug/kg/min, 1 times / day
Route: intravenous
Route: single
Dose: 9.58 ug/kg/min, 1 times / day
Sources: Page: -
unhealthy
n = 1301
Health Status: unhealthy
Condition: hypertension
Sex: M+F
Population Size: 1301
Sources: Page: -
Atrial flutter Disc. AE
9.58 ug/kg/min 1 times / day single, intravenous
Recommended
Dose: 9.58 ug/kg/min, 1 times / day
Route: intravenous
Route: single
Dose: 9.58 ug/kg/min, 1 times / day
Sources: Page: -
unhealthy
n = 1301
Health Status: unhealthy
Condition: hypertension
Sex: M+F
Population Size: 1301
Sources: Page: -
Atrioventricular block complete Disc. AE
9.58 ug/kg/min 1 times / day single, intravenous
Recommended
Dose: 9.58 ug/kg/min, 1 times / day
Route: intravenous
Route: single
Dose: 9.58 ug/kg/min, 1 times / day
Sources: Page: -
unhealthy
n = 1301
Health Status: unhealthy
Condition: hypertension
Sex: M+F
Population Size: 1301
Sources: Page: -
Atrioventricular block second degree Disc. AE
9.58 ug/kg/min 1 times / day single, intravenous
Recommended
Dose: 9.58 ug/kg/min, 1 times / day
Route: intravenous
Route: single
Dose: 9.58 ug/kg/min, 1 times / day
Sources: Page: -
unhealthy
n = 1301
Health Status: unhealthy
Condition: hypertension
Sex: M+F
Population Size: 1301
Sources: Page: -
Bradycardia Disc. AE
9.58 ug/kg/min 1 times / day single, intravenous
Recommended
Dose: 9.58 ug/kg/min, 1 times / day
Route: intravenous
Route: single
Dose: 9.58 ug/kg/min, 1 times / day
Sources: Page: -
unhealthy
n = 1301
Health Status: unhealthy
Condition: hypertension
Sex: M+F
Population Size: 1301
Sources: Page: -
Cardiac failure congestive Disc. AE
9.58 ug/kg/min 1 times / day single, intravenous
Recommended
Dose: 9.58 ug/kg/min, 1 times / day
Route: intravenous
Route: single
Dose: 9.58 ug/kg/min, 1 times / day
Sources: Page: -
unhealthy
n = 1301
Health Status: unhealthy
Condition: hypertension
Sex: M+F
Population Size: 1301
Sources: Page: -
Cardio-respiratory arrest Disc. AE
9.58 ug/kg/min 1 times / day single, intravenous
Recommended
Dose: 9.58 ug/kg/min, 1 times / day
Route: intravenous
Route: single
Dose: 9.58 ug/kg/min, 1 times / day
Sources: Page: -
unhealthy
n = 1301
Health Status: unhealthy
Condition: hypertension
Sex: M+F
Population Size: 1301
Sources: Page: -
Flushing Disc. AE
9.58 ug/kg/min 1 times / day single, intravenous
Recommended
Dose: 9.58 ug/kg/min, 1 times / day
Route: intravenous
Route: single
Dose: 9.58 ug/kg/min, 1 times / day
Sources: Page: -
unhealthy
n = 1301
Health Status: unhealthy
Condition: hypertension
Sex: M+F
Population Size: 1301
Sources: Page: -
Haemorrhage Disc. AE
9.58 ug/kg/min 1 times / day single, intravenous
Recommended
Dose: 9.58 ug/kg/min, 1 times / day
Route: intravenous
Route: single
Dose: 9.58 ug/kg/min, 1 times / day
Sources: Page: -
unhealthy
n = 1301
Health Status: unhealthy
Condition: hypertension
Sex: M+F
Population Size: 1301
Sources: Page: -
Hypertension Disc. AE
9.58 ug/kg/min 1 times / day single, intravenous
Recommended
Dose: 9.58 ug/kg/min, 1 times / day
Route: intravenous
Route: single
Dose: 9.58 ug/kg/min, 1 times / day
Sources: Page: -
unhealthy
n = 1301
Health Status: unhealthy
Condition: hypertension
Sex: M+F
Population Size: 1301
Sources: Page: -
Hypotension Disc. AE
9.58 ug/kg/min 1 times / day single, intravenous
Recommended
Dose: 9.58 ug/kg/min, 1 times / day
Route: intravenous
Route: single
Dose: 9.58 ug/kg/min, 1 times / day
Sources: Page: -
unhealthy
n = 1301
Health Status: unhealthy
Condition: hypertension
Sex: M+F
Population Size: 1301
Sources: Page: -
Hypoxia Disc. AE
9.58 ug/kg/min 1 times / day single, intravenous
Recommended
Dose: 9.58 ug/kg/min, 1 times / day
Route: intravenous
Route: single
Dose: 9.58 ug/kg/min, 1 times / day
Sources: Page: -
unhealthy
n = 1301
Health Status: unhealthy
Condition: hypertension
Sex: M+F
Population Size: 1301
Sources: Page: -
Incision site complication Disc. AE
9.58 ug/kg/min 1 times / day single, intravenous
Recommended
Dose: 9.58 ug/kg/min, 1 times / day
Route: intravenous
Route: single
Dose: 9.58 ug/kg/min, 1 times / day
Sources: Page: -
unhealthy
n = 1301
Health Status: unhealthy
Condition: hypertension
Sex: M+F
Population Size: 1301
Sources: Page: -
Low cardiac output syndrome Disc. AE
9.58 ug/kg/min 1 times / day single, intravenous
Recommended
Dose: 9.58 ug/kg/min, 1 times / day
Route: intravenous
Route: single
Dose: 9.58 ug/kg/min, 1 times / day
Sources: Page: -
unhealthy
n = 1301
Health Status: unhealthy
Condition: hypertension
Sex: M+F
Population Size: 1301
Sources: Page: -
Myocardial infarction Disc. AE
9.58 ug/kg/min 1 times / day single, intravenous
Recommended
Dose: 9.58 ug/kg/min, 1 times / day
Route: intravenous
Route: single
Dose: 9.58 ug/kg/min, 1 times / day
Sources: Page: -
unhealthy
n = 1301
Health Status: unhealthy
Condition: hypertension
Sex: M+F
Population Size: 1301
Sources: Page: -
Myocardial ischaemia Disc. AE
9.58 ug/kg/min 1 times / day single, intravenous
Recommended
Dose: 9.58 ug/kg/min, 1 times / day
Route: intravenous
Route: single
Dose: 9.58 ug/kg/min, 1 times / day
Sources: Page: -
unhealthy
n = 1301
Health Status: unhealthy
Condition: hypertension
Sex: M+F
Population Size: 1301
Sources: Page: -
Pallor Disc. AE
9.58 ug/kg/min 1 times / day single, intravenous
Recommended
Dose: 9.58 ug/kg/min, 1 times / day
Route: intravenous
Route: single
Dose: 9.58 ug/kg/min, 1 times / day
Sources: Page: -
unhealthy
n = 1301
Health Status: unhealthy
Condition: hypertension
Sex: M+F
Population Size: 1301
Sources: Page: -
Pulmonary hypertension Disc. AE
9.58 ug/kg/min 1 times / day single, intravenous
Recommended
Dose: 9.58 ug/kg/min, 1 times / day
Route: intravenous
Route: single
Dose: 9.58 ug/kg/min, 1 times / day
Sources: Page: -
unhealthy
n = 1301
Health Status: unhealthy
Condition: hypertension
Sex: M+F
Population Size: 1301
Sources: Page: -
Respiratory arrest Disc. AE
9.58 ug/kg/min 1 times / day single, intravenous
Recommended
Dose: 9.58 ug/kg/min, 1 times / day
Route: intravenous
Route: single
Dose: 9.58 ug/kg/min, 1 times / day
Sources: Page: -
unhealthy
n = 1301
Health Status: unhealthy
Condition: hypertension
Sex: M+F
Population Size: 1301
Sources: Page: -
Supraventricular extrasystoles Disc. AE
9.58 ug/kg/min 1 times / day single, intravenous
Recommended
Dose: 9.58 ug/kg/min, 1 times / day
Route: intravenous
Route: single
Dose: 9.58 ug/kg/min, 1 times / day
Sources: Page: -
unhealthy
n = 1301
Health Status: unhealthy
Condition: hypertension
Sex: M+F
Population Size: 1301
Sources: Page: -
Supraventricular tachycardia Disc. AE
9.58 ug/kg/min 1 times / day single, intravenous
Recommended
Dose: 9.58 ug/kg/min, 1 times / day
Route: intravenous
Route: single
Dose: 9.58 ug/kg/min, 1 times / day
Sources: Page: -
unhealthy
n = 1301
Health Status: unhealthy
Condition: hypertension
Sex: M+F
Population Size: 1301
Sources: Page: -
Tachycardia Disc. AE
9.58 ug/kg/min 1 times / day single, intravenous
Recommended
Dose: 9.58 ug/kg/min, 1 times / day
Route: intravenous
Route: single
Dose: 9.58 ug/kg/min, 1 times / day
Sources: Page: -
unhealthy
n = 1301
Health Status: unhealthy
Condition: hypertension
Sex: M+F
Population Size: 1301
Sources: Page: -
Thrombocytopenia Disc. AE
9.58 ug/kg/min 1 times / day single, intravenous
Recommended
Dose: 9.58 ug/kg/min, 1 times / day
Route: intravenous
Route: single
Dose: 9.58 ug/kg/min, 1 times / day
Sources: Page: -
unhealthy
n = 1301
Health Status: unhealthy
Condition: hypertension
Sex: M+F
Population Size: 1301
Sources: Page: -
Ventricular fibrillation Disc. AE
9.58 ug/kg/min 1 times / day single, intravenous
Recommended
Dose: 9.58 ug/kg/min, 1 times / day
Route: intravenous
Route: single
Dose: 9.58 ug/kg/min, 1 times / day
Sources: Page: -
unhealthy
n = 1301
Health Status: unhealthy
Condition: hypertension
Sex: M+F
Population Size: 1301
Sources: Page: -
Ventricular tachycardia Disc. AE
9.58 ug/kg/min 1 times / day single, intravenous
Recommended
Dose: 9.58 ug/kg/min, 1 times / day
Route: intravenous
Route: single
Dose: 9.58 ug/kg/min, 1 times / day
Sources: Page: -
unhealthy
n = 1301
Health Status: unhealthy
Condition: hypertension
Sex: M+F
Population Size: 1301
Sources: Page: -
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Time-dependent cardioprotection with calcium antagonism and experimental studies with clevidipine in ischemic-reperfused pig hearts: part I.
2002 Aug
Effects of fenoldopam, a dopamine D-1 agonist, and clevidipine, a calcium channel antagonist, in acute renal failure in anesthetized rats.
2002 May
Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting calcium antagonist for rapid blood pressure control.
2004 Fall
Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81.
2006 May
New therapeutic perspectives with clevidipine: an ultra-short-acting intravenous Ca2+ channel blocker.
2007 Sep
Patents

Sample Use Guides

Initial dose: Initiate the intravenous infusion of Cleviprex at 1-2 mg/hour. Dose titration: The dose may be doubled at short (90 second) intervals initially. As the blood pressure approaches goal, the increase in doses should be less than doubling and the time between dose adjustments should be lengthened to every 5-10 minutes. An approximately 1-2 mg/hour increase will generally produce an additional 2-4 mmHg decrease in systolic pressure. Maintenance dose: The desired therapeutic response for most patients occurs at doses of 4-6 mg/hour. Patients with severe hypertension may require doses up to 32 mg/hour, but there is limited experience at this dose rate. Maximum dose: Most patients were treated with maximum doses of 16 mg/hour or less.There is limited short-term experience with doses up to 32 mg/hour. Because of lipid load restrictions, no more than 1000 mL or an average of 21 mg/hour of Cleviprex infusion is recommended per 24 hour period. In clinical trials, 55 hypertensive patients were treated with >500mL of Cleviprex infusion per 24 hour period. There is little experience with infusion durations beyond 72 hours at any dose.
Route of Administration: Intravenous
In Vitro Use Guide
Clevidipine completely reversed U46619-induced contraction (EC50 = 3.88 +/- 0.84 x 10(-6) mol/L) of human internal mammary artery.
Substance Class Chemical
Created
by admin
on Sat Jun 26 09:31:33 UTC 2021
Edited
by admin
on Sat Jun 26 09:31:33 UTC 2021
Record UNII
19O2GP3B7Q
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CLEVIDIPINE
DASH   INN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
CLEVIDEPINE BUTYRATE [VANDF]
Common Name English
CLEVIDIPINE [MI]
Common Name English
CLEVIDIPINE [ORANGE BOOK]
Common Name English
3,5-PYRIDINEDICARBOXYLIC ACID, 4-(2,3-DICHLOROPHENYL)-1,4-DIHYDRO-2,6-DIMETHYL-, 3-METHYL 5-((1-OXOBUTOXY)METHYL) ESTER
Common Name English
CLEVIDEPINE
VANDF  
Common Name English
CLEVIDIPINE [VANDF]
Common Name English
CLEVIDEPINE BUTYRATE
VANDF  
Common Name English
(BUTANOYLOXY)METHYL METHYL (4RS)-4-(2,3-DICHLOROPHENYL)-2,6-DIMETHYL-1,4-DIHYDROPYRIDINE-3,5-DICARBOXYLATE
Systematic Name English
CLEVIDIPINE BUTYRATE [VANDF]
Common Name English
H-324/38
Code English
CLEVIDIPINE [USAN]
Common Name English
CLEVIDIPINE [MART.]
Common Name English
CLEVIDIPINE BUTYRATE [ORANGE BOOK]
Common Name English
CLEVIDIPINE [WHO-DD]
Common Name English
H324/38
Code English
CLEVIPREX
Brand Name English
CLEVIDIPINE BUTYRATE
ORANGE BOOK   VANDF  
Common Name English
CLEVIDEPINE [VANDF]
Common Name English
CLEVIDIPINE [INN]
Common Name English
3,5-PYRIDINEDICARBOXYLIC ACID, 4-(2,3-DICHLOROPHENYL)-1,4-DIHYDRO-2,6-DIMETHYL-, METHYL (1-OXOBUTOXY)METHYL ESTER
Common Name English
Classification Tree Code System Code
NDF-RT N0000007556
Created by admin on Sat Jun 26 09:31:33 UTC 2021 , Edited by admin on Sat Jun 26 09:31:33 UTC 2021
WHO-ATC C08CA16
Created by admin on Sat Jun 26 09:31:33 UTC 2021 , Edited by admin on Sat Jun 26 09:31:33 UTC 2021
NDF-RT N0000175421
Created by admin on Sat Jun 26 09:31:33 UTC 2021 , Edited by admin on Sat Jun 26 09:31:33 UTC 2021
NDF-RT N0000000069
Created by admin on Sat Jun 26 09:31:33 UTC 2021 , Edited by admin on Sat Jun 26 09:31:33 UTC 2021
NCI_THESAURUS C333
Created by admin on Sat Jun 26 09:31:33 UTC 2021 , Edited by admin on Sat Jun 26 09:31:33 UTC 2021
WHO-VATC QC08CA16
Created by admin on Sat Jun 26 09:31:33 UTC 2021 , Edited by admin on Sat Jun 26 09:31:33 UTC 2021
Code System Code Type Description
CAS
166432-28-6
Created by admin on Sat Jun 26 09:31:33 UTC 2021 , Edited by admin on Sat Jun 26 09:31:33 UTC 2021
SUPERSEDED
IUPHAR
7468
Created by admin on Sat Jun 26 09:31:33 UTC 2021 , Edited by admin on Sat Jun 26 09:31:33 UTC 2021
PRIMARY
DRUG BANK
DB04920
Created by admin on Sat Jun 26 09:31:33 UTC 2021 , Edited by admin on Sat Jun 26 09:31:33 UTC 2021
PRIMARY
INN
7490
Created by admin on Sat Jun 26 09:31:33 UTC 2021 , Edited by admin on Sat Jun 26 09:31:33 UTC 2021
PRIMARY
ChEMBL
CHEMBL1237132
Created by admin on Sat Jun 26 09:31:33 UTC 2021 , Edited by admin on Sat Jun 26 09:31:33 UTC 2021
PRIMARY
NCI_THESAURUS
C72727
Created by admin on Sat Jun 26 09:31:33 UTC 2021 , Edited by admin on Sat Jun 26 09:31:33 UTC 2021
PRIMARY
EVMPD
SUB06655MIG
Created by admin on Sat Jun 26 09:31:33 UTC 2021 , Edited by admin on Sat Jun 26 09:31:33 UTC 2021
PRIMARY
EPA CompTox
167221-71-8
Created by admin on Sat Jun 26 09:31:33 UTC 2021 , Edited by admin on Sat Jun 26 09:31:33 UTC 2021
PRIMARY
RXCUI
977863
Created by admin on Sat Jun 26 09:31:33 UTC 2021 , Edited by admin on Sat Jun 26 09:31:33 UTC 2021
PRIMARY
FDA UNII
19O2GP3B7Q
Created by admin on Sat Jun 26 09:31:33 UTC 2021 , Edited by admin on Sat Jun 26 09:31:33 UTC 2021
PRIMARY
PUBCHEM
153994
Created by admin on Sat Jun 26 09:31:33 UTC 2021 , Edited by admin on Sat Jun 26 09:31:33 UTC 2021
PRIMARY
DRUG CENTRAL
674
Created by admin on Sat Jun 26 09:31:33 UTC 2021 , Edited by admin on Sat Jun 26 09:31:33 UTC 2021
PRIMARY
WIKIPEDIA
Clevidipine
Created by admin on Sat Jun 26 09:31:33 UTC 2021 , Edited by admin on Sat Jun 26 09:31:33 UTC 2021
PRIMARY
RXCUI
233603
Created by admin on Sat Jun 26 09:31:33 UTC 2021 , Edited by admin on Sat Jun 26 09:31:33 UTC 2021
ALTERNATIVE
MESH
C118563
Created by admin on Sat Jun 26 09:31:33 UTC 2021 , Edited by admin on Sat Jun 26 09:31:33 UTC 2021
PRIMARY
CAS
167221-71-8
Created by admin on Sat Jun 26 09:31:33 UTC 2021 , Edited by admin on Sat Jun 26 09:31:33 UTC 2021
PRIMARY
MERCK INDEX
M3620
Created by admin on Sat Jun 26 09:31:33 UTC 2021 , Edited by admin on Sat Jun 26 09:31:33 UTC 2021
PRIMARY Merck Index
Related Record Type Details
ENANTIOMER -> RACEMATE
BINDER->LIGAND
BINDING
ENANTIOMER -> RACEMATE
EXCRETED UNCHANGED
No intact parent compound is recovered in urine or feces, suggesting that clevidipine is completely and rapidly metabolized.
FECAL; URINE
TARGET -> INHIBITOR
Related Record Type Details
METABOLITE -> PARENT
MAJOR
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC